Pair page
BPC-157 with MK-677
Mechanism-tag overlap and published literature for BPC-157 and MK-677, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
oral-ghrelin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and MK-677 have published these mechanism-level observations. Not a co-administration recommendation.
Tissue repair support during the high-appetite anabolic window. Users rehabbing an injury while using MK-677 for lean-mass support commonly pair them. BPC-157's local NO/VEGFR2 pathway is independent of the GH axis.
Quick facts
BPC-157
MK-677
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2011 | MK-677 | Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183… PMID 20855119 | human trial |
| 2008 | MK-677 | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID:… PMID 18981485 | human trial |
| 2005 | MK-677 | Khojasteh-Bakht SC, Jones HM, Hirota T, Chen J, Lin DC, Harms AC, Vicini P, Cutler DL, Lalovic B. Pharmacokinetics of ibutamoren mesylate (MK-677) in healthy subjects. Br J Clin Pharmacol. 2005;59(5):595-602. | human study |
| 2004 | MK-677 | Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Aspray TJ, Boonen S, Dalsky G, Dietz F, Dressler DE, Lang T, Papanicolaou DA. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2… | human study |
| 1999 | MK-677 | Murphy MG, Bach MA, Plotkin D, Bolognese J, Thompson J, Lichtlen P, Sullivan P, Walton H, Ying S, Daifotis AG. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res.… | human study |
| 1998 | MK-677 | Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditur… PMID 9661080 | human study |
| 1996 | MK-677 | Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogo… PMID 8954023 | human study |
| 2025 | MK-677 | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2025 | MK-677 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2). Pharmacy Compounding Advisory Committee. Updated 2025. | regulatory / registry |
| 2020 | MK-677 | Shiimura Y, Horita S, Hamamoto A, Asada H, Hirata K, Tanaka M, Mori K, Uemura T, Kobayashi T, Iwata S, Kojima M. Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode. Nat Commun. 2020;11(1):4160. PMID: 32814772. PMID 32814772 | research article |
| 2018 | MK-677 | Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28870384. PMID 28870384 | research article |
| 2001 | MK-677 | Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Cli… PMID 11238495 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 and MK-677 been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and MK-677. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and MK-677 share?
BPC-157 and MK-677 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and MK-677?
BPC-157: Category 2 (reclassification pending). MK-677: Not approved; WADA banned. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and MK-677?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the MK-677 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026